There is a new tool to assist in the fight against porcine reproductive and respiratory syndrome. Fostera PRRS, a modified-live vaccine for growing pigs from Pfizer Animal Health, brings a new standard of innovation to the costly battle against the disease.
The Pfizer Animal Health research and development team created unique cell lines that were able to express a newly discovered key receptor protein for the PRRS virus.
“With more than half of weaning-age, PRRS-negative pigs becoming infected before going to market, this innovative vaccine helps protect growing pigs against a PRRS challenge,” says Steve Sornsen, DVM, senior director, Veterinary Business Solutions at Pfizer.
A challenge study demonstrated that Fostera PRRS reduced lung lesions by 84 percent and reduced overall respiratory clinical signs by 80 percent. The product is the first and only PRRS vaccine to earn the label claim to aid in prevention of PRRS respiratory disease.
Additionally, results showed vaccination with Fostera PRRS improved pigs’ average daily gain by 2.5 times compared to pigs in the placebo group.
“Fostera PRRS helps optimize performance by minimizing the adverse effects of a subsequent PRRS challenge, thereby allowing growing pigs to maximize their post-challenge weight gain,” says Doug King, DVM, senior veterinarian at Pfizer.
Fostera PRRS is supported by in-field resources and diagnostics to help veterinarians and producers tackle this critical disease challenge.
The vaccine is available from your veterinarian or animal health supplier. For more information, ask your veterinarian or Pfizer representative, visit PfizerPork.com/FosteraPRRS or call toll-free (855) 424-7349.